Bromide

Bromide

SCHEMBL1880908

Br.CCCCCCCCCCCCCCc1cn(-c2ccccc2)nn1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.69
CYP19A1 P11511 6/20 0.59
NOTUM Q6P988 2/20 0.55
MAOA P21397 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
DRD2 P14416 4/20 0.53
DRD3 P35462 4/20 0.53
DDX3X O00571 4/20 0.53
DRD4 P21917 2/20 0.51
GABRA2 P47869 1/20 0.49
GABRB2 P47870 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1890839 1.00 MIF (0.69) MIFCYP19A1NOTUMMAOAL3MBTL1
Bromide SCHEMBL1880796 1.00 MIF (0.69) MIFCYP19A1NOTUMMAOAL3MBTL1
Bromide SCHEMBL1883955 1.00 MIF (0.69) MIFCYP19A1NOTUMMAOAL3MBTL1
Bromide SCHEMBL1886330 0.98 MIF (0.71) MIFCYP19A1NOTUMMAOAL3MBTL1
SCHEMBL16271203 0.98 MIF (0.71) MIFCYP19A1NOTUMMAOAL3MBTL1
Bromide SCHEMBL1894577 0.87 NOTUM (0.62) MIFCYP19A1NOTUMMAOAL3MBTL1
SCHEMBL12601113 0.85 NOTUM (0.64) MIFCYP19A1NOTUMMAOAL3MBTL1
SCHEMBL18031111 0.84 MIF (0.97) MIFCYP19A1DDX3X
SCHEMBL15923549 0.84 MIF (0.97) MIFCYP19A1DDX3X
SCHEMBL3431081 0.83 DDX3X (0.55) MIFCYP19A1DDX3XGABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254871-B1 SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS UNIV DRESDEN TECH (DE) 2016-11-09 EP disclosed
US-9260397-B2 Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof TECHNISCHE UNIVERSITAET DRESDEN (DE) 2016-02-16 US disclosed
US-20110105761-A1 Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof TECHNISCHE UNIVERSITAET DRESDEN (DE) 2011-05-05 US disclosed
EP-2254871-A1 SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS Technische Universität Dresden (DE) 2010-12-01 EP disclosed
WO-2009095012-A1 SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF Technische Universität Dresden (DE) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105761-A1 Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof RDX, HAX1, CHRM2 MIF 3029/4885CYP19A1 1138/4885NOTUM 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.